Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY PHASE II RESULTS WITH LAVENGRATINIB (ABSK061) FOR THE TREATMENT OF ACHONDROPLASIA

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced the positive preliminary efficacy results from the Phase II clinical study of lavengratinib (ABSK061), a selective orally available small-molecule FGFR2/3 inhibitor, in children with achondroplasia ("**ACH**"). In the first and lowest dose cohort of 0.064mg/kg QD, children aged 6 years and older with ACH who received lavengratinib for 27 weeks achieved a mean increase of +2.4 cm/year in annualized height velocity ("**AHV**") from baseline, with a 100% responder rate*. Lavengratinib was well-tolerated with no observed FGFR1 or FGFR2-associated adverse events ("**AEs**").

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK061 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, 21 September 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics Announces Positive Preliminary Phase II Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia

On 21 September 2026, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced positive preliminary efficacy results from the Phase II clinical study of lavengratinib (ABSK061), a selective orally available small-molecule FGFR2/3 inhibitor, in children with achondroplasia ("**ACH**"). In the first and lowest dose cohort of 0.064mg/kg QD, children aged 6 years and older with ACH who received lavengratinib for 27 weeks achieved a mean increase of +2.4 cm/year in annualized height velocity ("**AHV**") from baseline, with a 100% responder rate*. Lavengratinib was well-tolerated with no observed FGFR1 or FGFR2-associated adverse events ("**AEs**").

ABSK061-202 is a Phase II, multicenter, open-label, dose-escalation study designed to evaluate the safety and efficacy of lavengratinib (once daily, orally administered) in children aged 3 to 12 years with ACH. All participants will receive lavengratinib for a planned treatment duration of 78 weeks. To date, all seven participants aged 6 to 12 years in the first and lowest dose cohort have completed six months of treatment and achieved encouraging preliminary results:

- **Preliminary data demonstrate positive signals for growth promotion.** At Week 27, the seven participants in the first and lowest dose cohort (0.064mg/kg, once daily) achieved a mean improvement of +2.4 cm/year in AHV from baseline, with a responder rate* of 100%. Participants enrolled in higher dose cohorts are currently receiving treatment.

- **Overall safety and tolerability were favorable.** To date, no serious adverse events ("**SAEs**") or treatment discontinuations due to AEs have been reported. No specific safety risks associated with FGFR pathway inhibition have been observed to date, including FGFR1 or FGFR2-associated AEs such as hyperphosphatemia and corneal toxicity.

- **Lavengratinib leverages Abbisko's unique oral mini-tablet formulation.** Abbisko's unique mini-tablet formulation, with each tablet being less than 3mm in diameter as compared to conventional tablets ~8-10mm in diameter, allows for easy administration in children. Such mini-tablets can be conveniently administered with food and drink.

The ABSK061-202 study has successfully completed the preliminary safety evaluation of the first three dose cohorts, with no safety concerns identified to date. Six-month efficacy and safety results are expected by the end of 2026, providing further evidence to support the evaluation of the clinical potential of lavengratinib in children with ACH.

* Responder is defined as a participant achieving an ≥25% improvement in AHV from baseline.

About Lavengratinib (ABSK061)

Lavengratinib is a novel, orally bioavailable, highly potent and selective small molecule inhibitor of FGFR2/3 independently discovered and wholly-owned by Abbisko Therapeutics. It is the first FGFR2/3 inhibitor to enter clinical trials globally. First-generation pan-FGFR inhibitors demonstrated clinical efficacy in multiple tumors carrying FGFR2/3 variants and have steadily gained regulatory approval globally. However, the therapeutic window of pan-FGFRs and their clinical efficacy have been limited by side effects associated with FGFR1 inhibition. By reducing FGFR1 activity while maintaining potency against FGFR2/3, lavengratinib is expected to achieve a wider therapeutic window with improved clinical efficacy as a new-generation of FGFR inhibitors. Lavengratinib for the treatment of achondroplasia has received both Rare Pediatric Disease Designation ("**RPDD**") and Orphan Drug Designation ("**ODD**") from the U.S. Food and Drug Administration ("**FDA**"), and its Phase II clinical trial is currently ongoing.

About Abbisko Therapeutics

Founded in 2016, Abbisko Therapeutics (HKEX: 02256) is a pharmaceutical company committed to the research, discovery, and development of innovative and differentiated medicines designed to address unmet medical needs in China and globally.

Adhering to international concepts and standards for drug development, Abbisko primarily centers on small molecules, emphasizing precision oncology and immuno-oncology, with a growing expansion into both non-oncology therapeutic areas and other modalities. Its self-developed Class 1 innovative drug, pimicotinib, has received approval from the China NMPA, while dozens of other candidates are currently in clinical development stages.

Abbisko Therapeutics is committed to creating first-in-class and best-in-class innovative drugs. Through an unwavering pursuit of scientific innovation, the company strives to provide transformative therapies with breakthrough efficacy for patients worldwide.

For more information, please visit www.abbisko.com.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.